We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Steroids Helping Albuterol Responders Exclusively (SHARE)

This study has been withdrawn prior to enrollment.
(We were unable to enroll a sufficient number of patients due to manpower.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00798616
First Posted: November 26, 2008
Last Update Posted: December 9, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospitals Cleveland Medical Center
  Purpose
The purpose of the study is to determine whether corticosteroids are beneficial to children with bronchiolitis whose breathing gets better after being given a breathing treatment with albuterol.

Condition Intervention
Bronchiolitis Drug: prednisolone or methylprednisolone Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol ("Albuterol Responders")?

Resource links provided by NLM:


Further study details as provided by University Hospitals Cleveland Medical Center:

Primary Outcome Measures:
  • respiratory rate and respiratory distress score [ Time Frame: 4 hours ]
  • length of hospitalization (actual and until meets "ready for discharge" criteria) [ Time Frame: variable, likely no more than 2 weeks ]

Secondary Outcome Measures:
  • need for increased respiratory support (intubation, CPAP, BiPAP) [ Time Frame: variable, likely up to 2 weeks ]
  • amount of oxygen used during hospitalization [ Time Frame: variable, likely less than 2 weeks ]
  • number of doses of bronchodilators used during hospitalization [ Time Frame: variable, likely no more than 2 weeks ]
  • total duration of symptoms [ Time Frame: variable, likely no more than 3 weeks ]
  • need for unanticipated medical care after discharge [ Time Frame: variable, likely no more than 3 weeks ]
  • tachycardia and/or hypertension during hospitalization [ Time Frame: variable, likely no more than 2 weeks ]

Enrollment: 0
Arms Assigned Interventions
Placebo Comparator: Responders/Placebo
Albuterol responders being given placebo
Drug: placebo
oral or IV placebo
Active Comparator: Responders/Steroids
albuterol responders being given steroids
Drug: prednisolone or methylprednisolone
either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
Other Names:
  • corticosteroids
  • Solu-Medrol
  • Orapred
Placebo Comparator: Non-responders/placebo
non-albuterol responders being given placebo
Drug: placebo
oral or IV placebo
Active Comparator: non-responders/steroids
non-albuterol responders being given steroids
Drug: prednisolone or methylprednisolone
either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
Other Names:
  • corticosteroids
  • Solu-Medrol
  • Orapred

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of bronchiolitis
  • Respiratory Distress Assessment Index score of 4 or more

Exclusion Criteria:

  • prior prescription of bronchodilators or inhaled corticosteroids
  • birth at <36 weeks gestation
  • chronic cardiac disease
  • chronic pulmonary disease (including asthma)
  • immunodeficiency
  • non-topical steroid use in the prior week
  • parents that don't understand English
  • baseline systolic blood pressure >118 mmHg
  • home oxygen use
  • evidence of systemic fungal or varicella infection
  • bronchodilator use in the prior week
  • allergy to albuterol or corticosteroids
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00798616


Locations
United States, Ohio
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Investigators
Principal Investigator: Steven L Shein, MD University Hospitals Cleveland Medical Center
  More Information

Publications:

Responsible Party: Steven Shein, Chief Resident, Department of Pediatrics, University Hospitals of Cleveland
ClinicalTrials.gov Identifier: NCT00798616     History of Changes
Other Study ID Numbers: UHC 07-08-36
First Submitted: November 25, 2008
First Posted: November 26, 2008
Last Update Posted: December 9, 2014
Last Verified: October 2010

Keywords provided by University Hospitals Cleveland Medical Center:
bronchiolitis
steroids
corticosteroids
albuterol
child
infant
pediatric

Additional relevant MeSH terms:
Bronchiolitis
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Prednisolone acetate
Methylprednisolone acetate
Prednisolone
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Albuterol
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Bronchodilator Agents
Anti-Asthmatic Agents